• 1
    Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med2004; 351: 16451654.
  • 2
    Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med2009; 361: 787794.
  • 3
    Moran E, Byren I, Atkins BL. The diagnosis and management of prosthetic joint infections. J Antimicrob Chemother2010; 65 (suppl 3): iii45iii54.
  • 4
    Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs2006; 66: 10891105.
  • 5
    Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn?J Antimicrob Chemother2008; 61: 235237.
  • 6
    Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA1998; 279: 15371541.
  • 7
    Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis1990; 162: 96102.
  • 8
    Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis2011; 52 (suppl 7): S487S492.
  • 9
    Cook PP, Gooch M, Rizzo S. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob Agents Chemother2011; 55: 55975601.
  • 10
    Bamberger D, Foxworth J, Bridwell D, Shain C, Gerding D. Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans. In: Lorian V, ed. Antibiotics in laboratory medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 719814.
  • 11
    Documed. Arzneimittel-Kompendium der Schweiz. Basel, Switzerland, 2012.
  • 12
    Wichelhaus TA. Antibiotika—Moderne Therapiekonzepte. Bremen: UNI-MED Verlag AG, 2004/2005.
  • 13
    Arancibia A, Guttmann J, Gonzalez G, Gonzalez C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother1980; 17: 199202.
  • 14
    Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother2007; 51: 32903297.
  • 15
    Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother1992; 36: 14371440.
  • 16
    Forth W, Henschler D, Rummel W, Starke K. Allgemeine und spezielle Pharmakologie und Toxikologie, 7th edn. Heidelberg, Berlin: Spektrum Akademischer Verlag, 1996.
  • 17
    Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis2009; 49: 325327.
  • 18
    Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet1992; 22: 4765.
  • 19
    Achermann Y, Eigenmann K, Ledergerber B et al. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection(in press); Doi:10.1007/s15010-012-0325-7.
  • 20
    Aboltins CA, Page MA, Buising KL et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect2007; 13: 586591.
  • 21
    Soriano A, Garcia S, Bori G et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect2006; 12: 930933.
  • 22
    Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother1997; 39: 235240.
  • 23
    Boselli E, Allaouchiche B. Diffusion in bone tissue of antibiotics. Presse Med1999; 28: 22652276.
  • 24
    Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis2012; 54: 393407.
  • 25
    Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet2009; 48: 89124.
  • 26
    San Juan R, Garcia-Reyne A, Caba P et al. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother2010; 54: 51615166.
  • 27
    Bergan T, Solhaug JH, Soreide O, Leinebo O. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand J Gastroenterol1985; 20: 945950.
  • 28
    Gomez J, Canovas E, Banos V et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother2011; 55: 43084310.
  • 29
    Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection2004; 32: 222228.
  • 30
    Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin Microbiol Infect2006; 12: 433439.
  • 31
    Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect2011; 17: 439444.
  • 32
    Soriano A, Gomez J, Gomez L et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis2007; 26: 353356.
  • 33
    Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis1992; 14: 12511253.
  • 34
    Senneville E, Joulie D, Legout L et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis2011; 53: 334340.
  • 35
    Tuohy M, Washington JA. Antimicrobial susceptibility of viridans group streptococci. Diagn Microbiol Infect Dis1997; 29: 277280.
  • 36
    Etienne J, Gruer LD, Fleurette J. Antibiotic susceptibility of streptococcal strains associated with infective endocarditis. Eur Heart J1984; 5 (suppl C): 3337.
  • 37
    Traub WH, Leonhard B. Antibiotic susceptibility of alpha- and nonhemolytic streptococci from patients and healthy adults to 24 antimicrobial drugs. Chemotherapy1997; 43: 123131.
  • 38
    Renneberg J, Niemann LL, Gutschik E. Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. J Antimicrob Chemother1997; 39: 135140.
  • 39
    Betriu C, Casado MC, Gomez M, Sanchez A, Palau ML, Picazo JJ. Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study. Diagn Microbiol Infect Dis1999; 33: 255260.
  • 40
    Tuohy MJ, Procop GW, Washington JA. Antimicrobial susceptibility of Abiotrophia adiacens and Abiotrophia defectiva. Diagn Microbiol Infect Dis2000; 38: 189191.
  • 41
    Conley J, Olson ME, Cook LS, Ceri H, Phan V, Davies HD. Biofilm formation by group A streptococci: is there a relationship with treatment failure?J Clin Microbiol2003; 41: 40434048.
  • 42
    Maduri-Traczewski M, Szymczak EG, Goldmann DA. In vitro activity of penicillin and rifampin against group B streptococci. Rev Infect Dis1983; 5 (suppl 3): S586S592.
  • 43
    Jeng A, Chen J, Katsivas T. Prosthetic valve endocarditis from Granulicatella adiacens (nutritionally variant streptococci). J Infect2005; 51: e125e129.
  • 44
    Rosenthal O, Woywodt A, Kirschner P, Haller H. Vertebral osteomyelitis and endocarditis of a pacemaker lead due to Granulicatella (Abiotrophia) adiacens. Infection2002; 30: 317319.
  • 45
    Sendi P, Christensson B, Uckay I et al. Group B Streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect2012; 79: 6469.
  • 46
    Moellering RC Jr, Wennersten C. Therapeutic potential of rifampin in enterococcal infections. Rev Infect Dis1983; 5 (suppl 3): S528S532.
  • 47
    Oill PA, Kalmanson GM, Guze LB. Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats. Antimicrob Agents Chemother1981; 20: 491492.
  • 48
    Iannini PB, Ehret J, Eickhoff TC. Effects of ampicillin–amikacin and ampicillin–rifampin on enterococci. Antimicrob Agents Chemother1976; 9: 448451.
  • 49
    Ryan JL, Pachner A, Andriole VT, Root RK. Enterococcal meningitis: combined vancomycin and rifampin therapy. Am J Med1980; 68: 449451.
  • 50
    Holmberg A, Morgelin M, Rasmussen M. Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother2012; 67: 433439.
  • 51
    Silvestri C, Cirioni O, Arzeni D et al. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Eur J Clin Microbiol Infect Dis2011; 31: 17591764.
  • 52
    Rasouli MR, Tripathi MS, Kenyon R, Wetters N, Della Valle CJ, Parvizi J. Low rate of infection control in enterococcal periprosthetic joint infections. Clin Orthop Relat Res2012; Doi:10.1007/s11999-012-2374-8 [Epub ahead of print].
  • 53
    Olsson J, Davidsson S, Unemo M et al. Antibiotic susceptibility in prostate-derived Propionibacterium acnes isolates. APMIS2012; 120: 778785.
  • 54
    Zappe B, Graf S, Ochsner PE, Zimmerli W, Sendi P. Propionibacterium spp. in prosthetic joint infections: a diagnostic challenge. Arch Orthop Trauma Surg2008; 128: 10391046.
  • 55
    Furustrand Tafin U, Corvec S, Betrisey B, Zimmerli W, Trampuz A. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother2012; 56: 18851891.
  • 56
    Ghosh M, Talwani R, Gilliam BL. Propionibacterium skull osteomyelitis treated with daptomycin. Clin Neurol Neurosurg2009; 111: 610612.
  • 57
    Jakab E, Zbinden R, Gubler J, Ruef C, von Graevenitz A, Krause M. Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J Biol Med1996; 69: 477482.
  • 58
    Levy PY, Fenollar F, Stein A et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis2008; 46: 18841886.
  • 59
    Lutz MF, Berthelot P, Fresard A et al. Arthroplastic and osteosynthetic infections due to Propionibacterium acnes: a retrospective study of 52 cases, 1995–2002. Eur J Clin Microbiol Infect Dis2005; 24: 739744.
  • 60
    Soderquist B, Holmberg A, Unemo M. Propionibacterium acnes as an etiological agent of arthroplastic and osteosynthetic infections—two cases with specific clinical presentation including formation of draining fistulae. Anaerobe2012; 16: 304306.
  • 61
    Zeller V, Ghorbani A, Strady C, Leonard P, Mamoudy P, Desplaces N. Propionibacterium acnes: an agent of prosthetic joint infection and colonization. J Infect2007; 55: 119124.
  • 62
    Aboltins CA, Dowsey MM, Buising KL et al. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect2011; 17: 862867.
  • 63
    Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty2011; 26: 104108.
  • 64
    Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis2009; 49: 10361043.
  • 65
    Martinez-Pastor JC, Munoz-Mahamud E, Vilchez F et al. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother2009; 53: 47724777.
  • 66
    Savage PB. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med2001; 33: 167171.
  • 67
    Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev1992; 56: 395411.
  • 68
    Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis1983; 5 (suppl 3): S407S411.
  • 69
    Drapeau CM, Grilli E, Petrosillo N. Rifampicin combined regimens for gram-negative infections: data from the literature. Int J Antimicrob Agents2010; 35: 3944.
  • 70
    Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev2010; 23: 1434.
  • 71
    Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis2009; 28: 12751279.
  • 72
    Varaldo PE, Debbia E, Schito GC. In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species. Antimicrob Agents Chemother1985; 27: 615618.
  • 73
    Obst G, Gagnon RF, Harris A, Prentis J, Richards GK. The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model. Am J Nephrol1989; 9: 414420.
  • 74
    Fietta A, Morosini M, Cascina A. Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis. J Chemother2001; 13: 167175.
  • 75
    Tsuji BT, Yang JC, Forrest A, Kelchlin PA, Smith PF. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. J Antimicrob Chemother2008; 62: 156160.
  • 76
    Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother2007; 51: 25402545.
  • 77
    Uckay I, Bernard L. Gram-negative versus gram-positive prosthetic joint infections. Clin Infect Dis2010; 50: 795.
  • 78
    Widmer AF, Colombo VE, Gachter A, Thiel G, Zimmerli W. Salmonella infection in total hip replacement: tests to predict the outcome of antimicrobial therapy. Scand J Infect Dis1990; 22: 611618.
  • 79
    van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis2012; 54: 755771.
  • 80
    James RC, Pierce JG, Okano A, Xie J, Boger DL. Redesign of glycopeptide antibiotics: back to the future. ACS Chem Biol2012; 7: 797804.
  • 81
    Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs2001; 61: 525551.
  • 82
    Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother2002; 50: 7377.
  • 83
    Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother2000; 44: 34383440.
  • 84
    Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Soderquist B. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. Eur J Clin Microbiol Infect Dis2010; 29: 591595.
  • 85
    Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother2009; 53: 11421148.
  • 86
    Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther2006; 28: 11551163.
  • 87
    Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis2007; 59: 173179.
  • 88
    Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?J Antimicrob Chemother2010; 65: 22242230.
  • 89
    Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc2004; 79: 11371144.
  • 90
    Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs2007; 67: 14831512.
  • 91
    LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother2004; 48: 46654672.
  • 92
    John AK, Baldoni D, Haschke M et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother2009; 53: 27192724.
  • 93
    Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother2007; 51: 42554260.
  • 94
    Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis2010; 50 (suppl 1): S10S15.
  • 95
    Figueroa DA, Mangini E, Amodio-Groton M et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis2009; 49: 177180.
  • 96
    Saleh-Mghir A, Muller-Serieys C, Dinh A, Massias L, Cremieux AC. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother2011; 55: 45894593.
  • 97
    Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res2006; 451: 3437.
  • 98
    Garrigos C, Murillo O, Euba G et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother2010; 54: 52515256.
  • 99
    Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med2007; 120: S13S20.